Compare Incyte Corporation (INCY) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vipshop Holdings Ltd - ADR — how do they compare? Incyte Corporation trades at $113.51 (market cap $22.85B), while Vipshop Holdings Ltd - ADR trades at $12.95 (market cap $6.05B). The key difference: Incyte Corporation is far larger — about 3.8× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.87% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Vipshop Holdings Ltd - ADR for 49 Days on average.
| INCY | VIPS | |
|---|---|---|
Market Cap | $22.85B | $6.05B |
Volume | 1,927,029 | 3,719,230 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $20.29 |
52-Week Low | $83.80 | $12.09 |
Typical Hold Time | 33 Days | 49 Days |
Enterprise Value | $18.35B | $2.87B |
Dividend Yield | — | 4.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Vipshop Holdings (VIPS) trades at $12.98, up 1.61% with mixed technical signals showing neutral overall momentum. The stock trades at attractive valuation multiples including P/E of 4.1x and P/S of 0.4x, supported by strong profitability with 24.4% ROE. Recent earnings showed Q2 2026 miss with $0.12 EPS versus $0.59 expected, reflecting challenging retail conditions as revenue declined to $105.9B in 2025.
The investment case balances deep value metrics against growth headwinds. Analyst consensus targets $16.17 (25% upside) with 54% buy ratings, though recent earnings misses and consumer spending concerns create near-term uncertainty. The company maintains strong cash generation with $9.1B operating cash flow in 2024, supporting shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
